PNDORA:OMXCOPPandora A/S Analysis
Data as of 2026-06-13 - not real-time
DKK 643.80
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Pandora’s stock is trading above its short‑ and medium‑term moving averages but just shy of the long‑term average, signaling a neutral price trend. Technical momentum is bullish with a positive MACD crossover, yet the RSI sits in the overbought zone, hinting at short‑term pressure near the recent resistance level.
Fundamentally, the company delivers strong gross and operating margins and a respectable dividend yield supported by solid cash flow, but growth is flat‑to‑slight and leverage is unusually high, dragging ROE to a low level. The latest earnings beat and an 11% price jump underscore short‑term optimism, while a DCF fair‑value estimate below the current price points to a valuation that may be stretched. Investors should weigh the attractive yield and margin stability against the debt load and limited growth outlook.
Fundamentally, the company delivers strong gross and operating margins and a respectable dividend yield supported by solid cash flow, but growth is flat‑to‑slight and leverage is unusually high, dragging ROE to a low level. The latest earnings beat and an 11% price jump underscore short‑term optimism, while a DCF fair‑value estimate below the current price points to a valuation that may be stretched. Investors should weigh the attractive yield and margin stability against the debt load and limited growth outlook.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- earnings beat and price momentum
- bullish MACD signal
- overbought RSI suggesting near‑term pullback risk
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- strong margins and dividend yield
- high debt‑to‑equity ratio
- valuation above intrinsic estimate
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- elevated leverage and low ROE
- flat organic growth prospects
- price trading above fair‑value benchmarks
Key Metrics & Analysis
Financial Health
Revenue Growth-3.20%
Profit Margin15.73%
P/E Ratio9.6
ROE129.43%
ROA17.33%
Debt/Equity420.80
P/B Ratio12.0
Op. Cash FlowDKK7.7B
Free Cash FlowDKK4.0B
Technical Analysis
TrendNeutral
RSI75.4
SupportDKK 507.80
ResistanceDKK 654.40
MA 20DKK 578.18
MA 50DKK 528.62
MA 200DKK 656.37
MACDBullish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair ValueDKK 501.41
Target PriceDKK 623.17
Upside/Downside-3.20%
GradeOvervalued
TypeValue
Dividend Yield3.42%
Risk Assessment
Beta0.34
Volatility50.16%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.